DRG Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and the total and diagnosed prevalence of RA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, France, Germany, Italy, Spain, United Kingdom, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology’s RA forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of RA?
- Of all people with RA, how many in each country under study have been formally diagnosed?
- Of all people diagnosed with RA, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RA over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts nine RA patient populations, as follows:
- Prevalent cases.
- Diagnosed prevalent cases.
- Undiagnosed prevalent cases.
- Diagnosed drug-treated prevalent cases.
- Diagnosed non-drug-treated prevalent cases.
- Incident cases.
- Diagnosed mild (2.61-3.2) prevalent cases.
- Diagnosed moderate (3.21-5.1) prevalent cases.
- Diagnosed severe (5.1+) prevalent cases.
Note: Coverage may vary by country.
- Rheumatoid Arthritis - Epidemiology - Emerging Markets
Author(s): Sunali D. Goonesekera, SM
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.